Five insights:
1. SpinalCyte’s website will publish both company-sponsored and independent fibroblast research studies on its website. SpinanlCyte CEO Pete O’Heeron believes the company’s technology is the “regenerative cell source of the future.”
2. The company focuses on regrowth of the spinal disc utilizing human dermal fibroblasts, which hold “significant advantages over mesenchymal stem cells,” according to Chief Scientific Officer, Thomas Ichim, MD.
3. An estimated 85 percent of people over the age of 50 have traces of degenerative disc disease and physicians perform over 1.3 million procedures to treat the disease annually.
4. A discectomy or spinal fusion are the most common treatments for patients with DDD.
5. CybroCell, the company’s off-the-shelf allogenic HDF product for DDD treatment, showed in a clinical trial that patients injected with the cell had sustained improvement in pain relief and increased back mobility.
More articles on biologics:
Neurosurgeon brings expertise to cannabis company as CMO — 5 insights
The next 5 years in spine: 5 surgeons on technology to watch
The highest value bone graft substitute for spine surgery: 5 findings
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
